Genelux Corporation (GNLX) Income Statement
GNLX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGNLX revenue and net income
Where GNLX's revenue goes
2025Each bar shows an amount and its share of revenue. GNLX kept −401,812.5% of revenue as net income.
GNLX profit margins
GNLX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | 0.0% | −91.0% | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GNLX quarterly EPS vs estimates
Genelux beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.20).
GNLX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $8,000 | $8,000 | $170,000 | $11.1M | $0 | $0 | $0 |
| Cost of revenue | $574,000 | $903,000 | $1.0M | $968,000 | $895,000 | $658,000 | $477,000 |
| Gross profit | −$566,000 | −$895,000 | −$848,000 | $10.1M | −$895,000 | −$658,000 | −$477,000 |
| Research & development | $19.9M | $19.0M | $12.8M | $9.1M | $6.3M | $6.2M | $7.5M |
| Sales, general & admin | $13.4M | $12.7M | $11.6M | $5.0M | $8.3M | $6.2M | $3.3M |
| Total operating expenses | $32.6M | $30.8M | $23.3M | $13.1M | $13.7M | $11.8M | $10.9M |
| Operating income | −$33.2M | −$31.7M | −$24.2M | −$3.0M | −$14.6M | −$12.4M | −$10.9M |
| Interest income | $1.1M | $1.5M | $244,000 | $0 | — | — | — |
| Interest expense | — | $0 | $4.0M | $1.4M | $1.8M | $1.2M | $761,000 |
| Income before taxes | −$32.1M | −$29.9M | −$28.3M | −$4.1M | −$16.4M | −$13.6M | −$11.6M |
| Income taxes | — | — | $850,105 | $1.1M | $1.4M | $1.2M | — |
| Net income | −$32.1M | −$29.9M | −$28.3M | −$5.2M | −$17.8M | −$14.9M | −$11.6M |
| EBITDA | −$31.6M | −$29.0M | −$26.5M | −$1.7M | −$13.7M | −$11.8M | −$10.5M |
| EPS (diluted) | −$0.86 | −$0.95 | −$1.21 | −$0.40 | −$0.57 | −$0.63 | — |
| Gross margin | −7,075.0% | −11,187.5% | −498.8% | 91.3% | — | — | — |
| Operating margin | −415,175.0% | −396,200.0% | −14,214.7% | −27.2% | — | — | — |
| Net margin | −401,812.5% | −373,362.5% | −16,645.3% | −47.0% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $8,000 | $0 | $0 | $452,000 | $896,000 | $0 | $0 | $8,000 | $1.5M | $0 |
| Cost of revenue | — | $1,000 | $148,000 | — | $143,000 | $139,000 | $452,000 | $224,000 | $204,000 | $248,000 | $201,000 | $272,000 |
| Gross profit | — | −$1,000 | −$140,000 | — | −$143,000 | −$139,000 | −$227,000 | −$224,000 | −$204,000 | −$240,000 | −$201,000 | −$272,000 |
| Research & development | $6.5M | $5.2M | $5.7M | $4.7M | $4.8M | $4.7M | $6.5M | $4.1M | $4.4M | $4.0M | $4.2M | $2.8M |
| Sales, general & admin | $3.1M | $3.1M | $3.8M | $3.5M | $3.0M | $3.1M | $3.2M | $2.9M | $2.5M | $4.1M | $2.8M | $2.5M |
| Total operating expenses | $9.6M | $8.4M | $9.3M | $8.2M | $7.6M | $7.8M | $9.7M | $6.9M | $6.7M | $7.9M | $7.0M | $5.0M |
| Operating income | −$9.6M | −$8.4M | −$9.4M | −$8.2M | −$7.8M | −$7.8M | −$9.7M | −$6.9M | −$6.9M | −$8.1M | −$7.0M | −$5.3M |
| Interest income | $174,000 | $243,000 | $165,000 | $244,000 | $336,000 | $324,000 | $402,000 | $474,000 | $316,000 | $265,000 | $240,000 | $4,000 |
| Interest expense | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $6,000 | $42,000 |
| Income before taxes | −$9.5M | −$7.1M | −$9.2M | −$8.0M | −$7.5M | −$7.5M | −$9.0M | −$6.5M | −$6.6M | −$7.8M | −$6.8M | −$5.3M |
| Income taxes | — | — | — | — | — | — | — | — | — | $204,724 | −$4.0M | −$38,000 |
| Net income | −$9.5M | −$7.1M | −$9.2M | −$8.0M | −$7.5M | −$7.5M | −$9.0M | −$6.5M | −$6.6M | −$7.8M | −$6.8M | −$5.3M |
| EBITDA | −$9.5M | −$7.0M | −$9.8M | −$7.8M | −$7.3M | −$7.4M | −$8.7M | −$6.2M | −$6.4M | −$7.6M | −$6.6M | −$5.1M |
| EPS (diluted) | −$0.21 | −$0.20 | −$0.24 | −$0.21 | −$0.20 | −$0.21 | −$0.25 | −$0.19 | −$0.22 | −$0.29 | −$0.25 | −$0.20 |
| Gross margin | — | — | −1,750.0% | — | — | −30.8% | −25.3% | — | — | −3,000.0% | −13.7% | — |
| Operating margin | — | — | −117,650.0% | — | — | −1,729.2% | −1,087.9% | — | — | −101,437.5% | −478.2% | — |
| Net margin | — | — | −115,587.5% | — | — | −1,657.5% | −1,001.8% | — | — | −98,125.0% | −462.2% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GNLX's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GNLX financial results
In fiscal year 2025 (ended December 31, 2025), Genelux reported revenue of $0.0 million, up 0.0% from the year before. It had a net loss of $32.1 million, a net profit margin of −401,812.5%. Diluted earnings per share came to −$0.86.
See the GNLX stock overview for the latest quote and news, or the GNLX chart for price history and technical indicators.
GNLX income statement FAQ
What is Genelux's annual revenue?
Genelux reported total revenue of $0.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 0.0% from $0.0 million the previous year.
Is Genelux profitable?
No. Genelux reported a net loss of $32.1 million in fiscal 2025, a net profit margin of −401,812.5%; its operating margin was −415,175.0%.
What is Genelux's gross margin?
Genelux's gross margin was −7,075.0% in fiscal 2025: for every $100 of revenue, Genelux kept $-7075 after the direct cost of its products and services.
How much does Genelux spend on research and development?
Genelux spent $19.9 million on research and development in fiscal 2025, 248,137.5% of revenue.
What are Genelux's earnings per share?
Genelux earned $-0.86 per diluted share in fiscal 2025, compared with $-0.95 a year earlier.
When will Genelux report its next earnings?
Genelux is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does Genelux's fiscal year end?
Genelux's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.